Multifaceted Inhibition of Anti-tumour Immune Mechanisms by Soluble Tumour Necrosis Factor Receptor Type I

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 1998 Aug 26

PMID 9708191

Citations 9

Authors

C L Selinsky

K L Boroughs

W A Halsey Jr

M D Howell

Affiliations

Soon will be listed here.

Abstract

Soluble tumour necrosis factor receptor type I (sTNFRI) is a potent inhibitor of TNF with the potential to suppress a variety of effector mechanisms important in tumour immunity. That sTNFRI influences tumour survival in vivo is suggested by results from human clinical trials of Ultrapheresis, an experimental extracorporeal treatment for cancer. While the considerable clinical benefit provided by Ultrapheresis is correlated with the removal of plasma sTNFRI, there is no direct evidence that sTNFRI inhibits immune mechanisms which mediate tumour cell elimination. To evaluate formally the ability of sTNFRI to inhibit these mechanisms, we have engineered sTNFRI production into the TNF-sensitive murine fibrosarcoma cell line, L929. Soluble TNFRI-secreting L929 cells display increased resistance to direct lysis by TNF, and to lysis by syngeneic lymphokine-activated killer cells and cytotoxic T cells. These findings confirm the suggestion that sTNFRI inhibits immunological mechanisms important in tumour cell eradication, and further support a role for sTNFRI in tumour survival in vivo. In addition, these observations suggest the development of methods for more specific removal and/or inactivation of sTNFRI as promising new avenues for cancer immunotherapy.

Citing Articles

Role of Salivary MicroRNA and Cytokines in the Diagnosis and Prognosis of Oral Squamous Cell Carcinoma.

Manzano-Moreno F, Costela-Ruiz V, Garcia-Recio E, Olmedo-Gaya M, Ruiz C, Reyes-Botella C Int J Mol Sci. 2021; 22(22).

PMID: 34830096 PMC: 8624198. DOI: 10.3390/ijms222212215.

The Neuroimmune and Neurotoxic Fingerprint of Major Neurocognitive Psychosis or Deficit Schizophrenia: a Supervised Machine Learning Study.

Al-Hakeim H, Almulla A, Maes M Neurotox Res. 2020; 37(3):753-771.

PMID: 31916129 DOI: 10.1007/s12640-019-00112-z.

From Normal to Obesity and Back: The Associations between Mitochondrial DNA Copy Number, Gender, and Body Mass Index.

Skuratovskaia D, Litvinova L, Vulf M, Zatolokin P, Popadin K, Mazunin I Cells. 2019; 8(5).

PMID: 31075887 PMC: 6562937. DOI: 10.3390/cells8050430.

Unleashing endogenous TNF-alpha as a cancer immunotherapeutic.

Josephs S, Ichim T, Prince S, Kesari S, Marincola F, Escobedo A J Transl Med. 2018; 16(1):242.

PMID: 30170620 PMC: 6119315. DOI: 10.1186/s12967-018-1611-7.

The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder.

Maes M, Carvalho A Mol Neurobiol. 2018; 55(12):8885-8903.

PMID: 29611101 DOI: 10.1007/s12035-018-1016-x.

References

Helson L, Green S, Carswell E, Old L . Effect of tumour necrosis factor on cultured human melanoma cells. Nature. 1975; 258(5537):731-2. DOI: 10.1038/258731a0. View

Kalmanti M, Karamolengou K, Dimitriou H, Tosca A, Vlachonikolis I, Peraki M . Serum levels of tumor necrosis factor and soluble interleukin 2 receptor as markers of disease activity and prognosis in childhood leukemia and lymphoma. Int J Hematol. 1993; 57(2):147-52. View

Ortaldo J, Mason L, Mathieson B, Liang S, Flick D, Herberman R . Mediation of mouse natural cytotoxic activity by tumour necrosis factor. Nature. 1986; 321(6071):700-2. DOI: 10.1038/321700a0. View

Smith R, Kirstein M, Fiers W, Baglioni C . Species specificity of human and murine tumor necrosis factor. A comparative study of tumor necrosis factor receptors. J Biol Chem. 1986; 261(32):14871-4. View

Wright S, Bonavida B . Studies on the mechanism of natural killer cell-mediated cytotoxicity. VII. functional comparison of human natural killer cytotoxic factors with recombinant lymphotoxin and tumor necrosis factor. J Immunol. 1987; 138(6):1791-8. View

Ostensen M, Thiele D, Lipsky P . Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells. J Immunol. 1987; 138(12):4185-91. View

Chomczynski P, Sacchi N . Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987; 162(1):156-9. DOI: 10.1006/abio.1987.9999. View

Ranges G, Figari I, Espevik T, Palladino Jr M . Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med. 1987; 166(4):991-8. PMC: 2188710. DOI: 10.1084/jem.166.4.991. View

NORTH R, Havell E . The antitumor function of tumor necrosis factor (TNF) II. Analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma. J Exp Med. 1988; 167(3):1086-99. PMC: 2188903. DOI: 10.1084/jem.167.3.1086. View

10.

Olsson I, Lantz M, Nilsson E, Peetre C, Thysell H, Grubb A . Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol. 1989; 42(3):270-5. DOI: 10.1111/j.1600-0609.1989.tb00111.x. View

11.

Stedman K, Campbell P . An [35S]methionine cytotoxicity assay requiring small numbers of effector and target cells. J Immunol Methods. 1989; 119(2):291-4. DOI: 10.1016/0022-1759(89)90409-2. View

12.

Lentz M . Continuous whole blood UltraPheresis procedure in patients with metastatic cancer. J Biol Response Mod. 1989; 8(5):511-27. View

13.

Engelmann H, Novick D, Wallach D . Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem. 1990; 265(3):1531-6. View

14.

Schall T, Lewis M, Koller K, Lee A, Rice G, Wong G . Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell. 1990; 61(2):361-70. DOI: 10.1016/0092-8674(90)90816-w. View

15.

Gatanaga T, Lentz R, Masunaka I, Tomich J, Jeffes 3rd E, Baird M . Identification of TNF-LT blocking factor(s) in the serum and ultrafiltrates of human cancer patients. Lymphokine Res. 1990; 9(2):225-9. View

16.

Gray P, Barrett K, Chantry D, Turner M, Feldmann M . Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein. Proc Natl Acad Sci U S A. 1990; 87(19):7380-4. PMC: 54750. DOI: 10.1073/pnas.87.19.7380. View

17.

Tite J . Evidence of a role for TNF-alpha in cytolysis by CD4+, class II MHC-restricted cytotoxic T cells. Immunology. 1990; 71(2):208-12. PMC: 1384305. View

18.

Gatanaga T, Hwang C, Kohr W, Cappuccini F, Lucci 3rd J, Jeffes E . Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci U S A. 1990; 87(22):8781-4. PMC: 55043. DOI: 10.1073/pnas.87.22.8781. View

19.

Himmler A, Kronke M, Scheurich P, Pfizenmaier K, Lantz M, Olsson I . Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein. DNA Cell Biol. 1990; 9(10):705-15. DOI: 10.1089/dna.1990.9.705. View

20.

Robaye B, Mosselmans R, Fiers W, Dumont J, Galand P . Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro. Am J Pathol. 1991; 138(2):447-53. PMC: 1886201. View